Skip to main content
ClinicalTrials.govcontrolled

Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)

ClinicalTrials.gov study NCT04146363. IPD Sharing: YES. Countries: 10. Publications: 11.

ShareScore

36/100

Overall dataset sharing score

Score breakdown

These five areas show where the dataset supports — or may limit — practical reuse.

Stewardship
12
Harmonization
12
Access
4
Reuse readiness
0
Engagement
8

Topics